Flemingsberg has a history of successful research and clinical development, not least in the field of advanced therapies and regenerative medicine.

The development offers hope for effective treatments for previously incurable heart diseases and cancers, as well as a number of autoimmune diseases such as diabetes, and also Parkinson’s and Alzheimer’s. These new methods use patients’ own cells to activate their own immune system for a more successful treatment.

At Karolinska Institutet, the researchers are developing new concepts in stem cell biology with the aim of finding new forms of treatment in a number of different areas. To help, Karolinska Institutet has a strong infrastructure, including in the form of Core Facilities.

One of these Core Facilities is Vecura, which among other things manufactures gene therapy vectors and cell therapy products for clinical trials. Vecura is part of the Clinical Research Center, Karolinska University Hospital Huddinge. The facility is certified by the Swedish Medical Products Agency and the National Board of Health and Welfare.

Vecura has been in operation since 1996 and has been of great importance for the development of the field of cell therapy and regenerative medicine in Sweden.

• Karolinska Institutet houses successful examples in both experimental stem cell research and applications in regenerative medicine.
• Karolinska Universitetssjukhuset has recently set up a large cell therapy program co-financed by Vinnova.
• Vecura is a core facility that manufactures gene therapy vectors and cell therapy products for clinical trials. The laboratory is part of the Clinical Research Center, Karolinska University Hospital in Huddinge.
• ANA Futura is a leading translational integrated research environment equipped for cutting-edge research, where boundaries between institutions and clinics are torn down and researchers collaborate based on common research profiles.

More about Scandinavia’s leading life science cluster can be found at Stockholm Business Region Development.